Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel technology to monitor ’hidden depths’ of silent killer

02.10.2003


New studies, ASTEROID and ORION, combine CRESTOR™ with cutting-edge imaging techniques, to be at the forefront of the fight against atherosclerosis



Details of two new studies announced by AstraZeneca at the XIIIth International Symposium on Atherosclerosis (ISA) could provide the clearest picture yet of the effects of statins on atherosclerosis, the main cause of coronary artery disease.

Each study is combining the highly effective statin CRESTOR (rosuvastatin) with cutting-edge imaging technology: intravascular ultrasound (IVUS)1 or magnetic resonance imaging (MRI)2,3; to evaluate whether CRESTOR can slow the progression or even lead to a regression of atherosclerosis.


Atherosclerosis gradually narrows the blood vessels, which can lead to a reduction in blood supply to vital organs such as the brain and heart, in some cases this can lead to angina and even a stroke or heart attack. A number of studies have shown that statins may slow the progression or even cause regression of atherosclerosis.4-7 Lowering LDL-cholesterol (LDL-C) slows the progression of atherosclerosis, however, it has been suggested that a larger reduction of at least 40% in LDL-C is needed to observe a regression of atherosclerosis.8,9

Treatment of atherosclerosis should be considered an important target as clinical studies have shown that <1% regression of coronary atherosclerosis is associated with major (70-80%) reductions in clinical events such as heart attacks.10

"Patients with atherosclerosis can show no symptoms for years before experiencing a serious, sometimes fatal, cardiovascular event – often making this disease a silent killer," explained Professor Gunnar Olsson, Vice President and Head of Cardiovascular Therapy Area, AstraZeneca.

"We know that raised LDL-C (or bad cholesterol) and low levels of HDL-C (or good cholesterol) are major risk factors for atherosclerosis and coronary heart disease. CRESTOR can reduce LDL-cholesterol significantly more than the same and some higher doses of other widely used statins and also provides the added benefit of raising HDL-cholesterol or good cholesterol. The three ongoing studies, ASTEROID, ORION and METEOR will demonstrate the benefits of CRESTOR on the atherosclerotic disease process thereby offering the potential for improving the prognosis of patients with, or at risk of, cardiovascular disease – the world’s number one killer."

ASTEROID1 and ORION2, 3, 11 are the first studies to evaluate CRESTOR 40mg – which has been shown to reduce LDL-C by up to 63%12 – on atherosclerosis using the novel imaging technologies IVUS and MRI.

Dr. Steven Nissen, Medical Director of the Cardiovascular Coordinating Center at the Cleveland Clinic Foundation, USA, is the principal investigator on the ASTEROID study. He commented: "Current imaging technology, such as coronary angiography, has only allowed us to visualise the narrowing of the blood vessel caused by atherosclerosis. IVUS lets us see the equally dangerous atherosclerosis hidden within the vessel wall. We are visualising not just the tip of the iceberg, but also what is below the waterline. CRESTOR, compared to other statins, provides outstanding efficacy both in terms of reducing LDL-C (bad cholesterol) and raising HDL-C (good cholesterol). ASTEROID will determine if a maximum dose (40mg) of this particular agent can actually reduce the burden of coronary atherosclerosis during two years of treatment."

"By using non-invasive MRI in ORION we will be able to measure the exact shape, size and distribution of atherosclerosis in blood vessels which may enable us to better evaluate the vascular effects of lipid-lowering therapy, and in clinical practice the use of MRI could facilitate early diagnosis and treatment," stated Dr. Baocheng Chu of the University of Washington School of Medicine, Seattle and investigator for ORION. He continued, "ORION will also show the benefits of CRESTOR in hypercholesterolaemic patients with established atherosclerotic disease."

ASTEROID, which started in November 2002, will recruit 450 patients with coronary artery disease from approximately 60 centres worldwide who will be treated with CRESTOR 40mg once daily for 24 months. The study will measure the percentage change in coronary artery volume at the end of treatment using IVUS. Coronary atherosclerosis will also be assessed using quantitative coronary angiography. 1

ORION has completed recruitment and 39 hypercholesterolaemic patients with established atherosclerosis have been randomised to receive CRESTOR 5mg or 40mg for 24 months. Baseline measurements from patients enrolled in the study were announced at ISA. The change in bilateral carotid artery wall volume will be measured by using MRI. Changes in the intima media thickness of the carotid arteries will also be measured using B-mode ultrasound. 2, 3, 11

METEOR is the third study within the GALAXY Programme evaluating the effects of CRESTOR on atherosclerosis.13 The study which started in August 2002 is using B-mode ultrasound to compare the effects of CRESTOR 40mg or placebo on intima media thickness of the carotid arteries in 840 asymptomatic patients with sub-clinical atherosclerosis who are not routinely treated with statin medication.

CRESTOR has now received regulatory approvals across three continents; America, including the USA, Europe and Asia, and has been launched in several countries worldwide. CRESTOR is awaiting approval in a number of other countries over the coming months.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.

AstraZeneca has more than 40 years experience in cardiovascular medicine and aims to increase lifespan and improve quality of life by reducing the risk, prevalence and impact of cardiovascular disease. AstraZeneca has a comprehensive cardiovascular portfolio including CRESTORTM, ATACANDTM, ZESTRILTM, TENORMINTM, SELOKEN ZOK /TOPROL-XLTM and PLENDILTM. This heritage is complemented by an innovative pipeline including the first oral direct thrombin inhibitor, EXANTATM, and a novel treatment for type 2 diabetes / metabolic syndrome, GALIDATM.



For further information please visit: http://www.AstraZenecaPressOffice.com.

Contact:
Julia Walker, Global PR Manager, Cardiovascular Therapy Area, AstraZeneca
Tel: 44-0-1625-510866
Mobile (in Japan): 81-0-90-5340-2294
Mobile: 44-0-7718-80-1984
Email: julia.walker@astrazeneca.com

Ellie Goss or Stephanie Martin, Shire Health International
Tel: 44-0-20-7471-1500
Ellie Goss’s mobile (in Japan): 81-0-90-5340-4799
Email: .goss@shirehealthinternational.com

Stephanie Martin | EurekAlert!
Further information:
http://www.tshg.com/
http://www.AstraZenecaPressOffice.com

More articles from Health and Medicine:

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

nachricht Alzheimer’s: Cellular Mechanism Provides Explanation Model for Declining Memory Performance
21.09.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

Im Focus: Complex hardmetal tools out of the 3D printer

For the first time, Fraunhofer IKTS shows additively manufactured hardmetal tools at WorldPM 2016 in Hamburg. Mechanical, chemical as well as a high heat resistance and extreme hardness are required from tools that are used in mechanical and automotive engineering or in plastics and building materials industry. Researchers at the Fraunhofer Institute for Ceramic Technologies and Systems IKTS in Dresden managed the production of complex hardmetal tools via 3D printing in a quality that are in no way inferior to conventionally produced high-performance tools.

Fraunhofer IKTS counts decades of proven expertise in the development of hardmetals. To date, reliable cutting, drilling, pressing and stamping tools made of...

Im Focus: Launch of New Industry Working Group for Process Control in Laser Material Processing

At AKL’16, the International Laser Technology Congress held in May this year, interest in the topic of process control was greater than expected. Appropriately, the event was also used to launch the Industry Working Group for Process Control in Laser Material Processing. The group provides a forum for representatives from industry and research to initiate pre-competitive projects and discuss issues such as standards, potential cost savings and feasibility.

In the age of industry 4.0, laser technology is firmly established within manufacturing. A wide variety of laser techniques – from USP ablation and additive...

Im Focus: New laser joining technologies at ‘K 2016’ trade fair

Every three years, the plastics industry gathers at K, the international trade fair for plastics and rubber in Düsseldorf. The Fraunhofer Institute for Laser Technology ILT will also be attending again and presenting many innovative technologies, such as for joining plastics and metals using ultrashort pulse lasers. From October 19 to 26, you can find the Fraunhofer ILT at the joint Fraunhofer booth SC01 in Hall 7.

K is the world’s largest trade fair for the plastics and rubber industry. As in previous years, the organizers are expecting 3,000 exhibitors and more than...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Experts from industry and academia discuss the future mobile telecommunications standard 5G

23.09.2016 | Event News

ICPE in Graz for the seventh time

20.09.2016 | Event News

Using mathematical models to understand our brain

16.09.2016 | Event News

 
Latest News

Chains of nanogold – forged with atomic precision

23.09.2016 | Life Sciences

New leukemia treatment offers hope

23.09.2016 | Health and Medicine

Self-assembled nanostructures hit their target

23.09.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>